Valtecne (VLT) Investor presentation summary

Financial performance highlights

• Revenues were €30.4M, nearly flat year-over-year, as medical growth offset industrial decline; medical now represents 70% of business.

• Value of Production fell 5.5% to €29.9M, mainly due to industrial segment weakness.

• Adjusted EBITDA rose 4.1% to €7.5M, with margin on VoP improving to 25.1%; reported EBITDA up 6.4% to €6.2M.

• Net profit increased 7.4% to €3.4M, driven by strong operating margins and financial results.

• Net financial position improved to a positive €6.8M, reflecting robust cash generation.

Business segment trends

• Medical revenues grew by 15.1%, now accounting for nearly 70% of total revenues.

• Industrial revenues declined by 25.4%, reflecting macroeconomic headwinds.

• Medical Value of Production increased by 6.9%, while industrial VoP dropped by 24.7%.

• Medical business growth offset industrial contraction, stabilizing overall revenues.

Growth and market positioning

• Achieved a 2018–2024 CAGR of 10.2%, outpacing the global orthopaedic market's 2.8% CAGR.

• Medical segment CAGR was 22.9% over the same period.

• Growth drivers include aging population, improved orthopaedic procedures, and rising incomes in emerging markets.